Persistence Market Research

Multiple Sclerosis Drugs Market to Surge at a Robust Pace in Terms of Revenue by 2021

The Multiple Sclerosis Drugs Market report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

 

New York, NY -- (SBWIRE) -- 04/28/2017 -- The global MS drugs market is segmented into small molecule MS drugs and biologics MS drugs. Major brands of small molecule MS drugs include Copaxone, Trimesta, Novantrone, Masitinib, Gilenya, Siponimod, Firategrast, Tecfidera and Aubagio. Some of the major biologics involved in the treatment of MS are Tysabri, Ocrelizumab, Zenapax, Arzerra, Avonex, Extavia, Rebif, Betaseron and Cinnovex. These small molecule and biologics MS drugs are mainly focused on the faster recovery from attacks and reduce progression of the disease.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/3647

In terms of geographic, North America dominates the global MS drugs market. The U.S. represents the largest market for MS drugs followed by Canada in North America. In Europe, France, Germany, Italy, Spain and the U.K. holds major share of MS drugs market. However, Asia is expected to show high growth rates in the next five years in global MS drugs market. This is due to many companies constructing their manufacturing and research facilities in the region. Developing regions have advantage over the developed regions due to low wages, availability of a large talent pool, less stringent environment and health and safety regulations. Japan, China and India are expected to be the fastest growing MS drugs markets in Asia.

In recent time, high unmet need of drugs for treatment of the disease and extensive R&D pipelines are some of the major drivers of the global MS drugs market. In addition, increased research in the field of MS to develop innovative therapies has also fueled the growth of global MS drugs market.

However, patent expiry of major drugs is key restraint of global MS drugs market. In addition, stringent regulatory hurdles also obstruct the growth of global MS drugs market. Advancement in biomedical science would develop opportunity for the global MS drugs market. Increasing mergers and acquisitions between manufacturing companies and rapid product launches are some of the major trends for global MS drugs market.

To view TOC of this report is available upon request @ http://www.persistencemarketresearch.com/toc/3647

Some of the major companies operating in the global MS drugs market are Bayer, GlaxoSmithKline, Teva Pharmaceutical, Novartis, Merck Serono, Sanofi, Pfizer, Abbvie, Biogen Idec, AB Science and Opexa.